Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, reports double digit growth in revenues and adjusted EBITDA for FY 2022.
Revenue rose organically by 16.2 percent, driven by all divisions. Adjusted EBITDA grew organically by 10.2 percent.
“In 2022, Gerresheimer has proven that it is a profitable growth company, accelerating growth across all businesses. We have exceeded our targets, while steering Gerresheimer successfully through a dynamic environment. Our strategic investments from recent years are paying off, resulting in significantly higher growth rates and returns. We will continue to leverage business opportunities and to accelerate our profitable growth path,” said Dietmar Siemssen, CEO of Gerresheimer AG. “Following a strong close to 2022, we have made a good start to 2023. Our order books are at record levels, and we expect continued double-digit growth in revenue and adjusted EBITDA, while further improving margins.”
- Consistent execution of strategy and strong fourth quarter performance has resulted in organic revenue growth of 16.2 percent for FY 2022
- Organic growth in adjusted EBITDA of 10.2 percent for FY 2022, ahead of guidance
- Q4 2022 delivered double-digit organic growth in revenues and adjusted EBITDA
- Good start to 2023, remaining on course for further profitable double-digit organic growth
The full report is available here.